Clinical impact of programmed cell death ligand 1 expression in colorectal cancer

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860

Classification and Regression Trees.

Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,522

Classification and Regression Trees.

Ryzin, J. V., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1986) · Journal of the American Statistical Association · doi:10.2307/2288003 · Cited by 20,825

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Classification and regression trees

Praagman, J. (1985) · European Journal of Operational Research · doi:10.1016/0377-2217(85)90321-2 · Cited by 10,053

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955

Human nutrition, the gut microbiome and the immune system

Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L., & Gordon, J. I. (2011) · Nature · doi:10.1038/nature10213 · Cited by 2,588

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157

Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer

Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314

Tissue expression of PD-L1 mediates peripheral T cell tolerance

Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018

Tumor-Infiltrating FOXP3 + T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., & Iacopetta, B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7229 · Cited by 991

Statistical Inference under Order Restrictions (The Theory and Application of Isotonic Regression)

Vincze, I., Barlow, R. E., Bartholomew, D. J., Bremner, J. M., & Brunk, H. D. (1973) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402630 · Cited by 842

Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776

The PD-1–PD-L pathway in immunological tolerance

Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 721

B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678

Tissue microarray technology for high-throughput molecular profiling of cancer

Kallioniemi, O.-P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.657 · Cited by 563

Tumour immunity: effector response to tumour and role of the microenvironment

Mantovani, A., Romero, P., Palucka, A. K., & Marincola, F. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60241-x · Cited by 537

Classification and Regression Trees

(2022) · The R Book · doi:10.1002/9781119634461.ch20 · Cited by 499

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

Zhang, L., Gajewski, T. F., & Kline, J. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 411

Expression of the B7 - related molecule B7 - H1 by glioma cells: a potential mechanism of immune paralysis

Wintterle, Schreiner, Mitsdoerffer, Schneider, Chen, Meyermann, Weller, M., & Wiendl (2003) · 中国神经肿瘤杂志 · Cited by 366

Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints

Martin, I., Jakob, M., Schäfer, D., Dick, W., Spagnoli, G., & Heberer, M. (2001) · Osteoarthritis and Cartilage · doi:10.1053/joca.2000.0366 · Cited by 360

High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients

Frey, D. M., Droeser, R. A., Viehl, C. T., Zlobec, I., Lugli, A., Zingg, U., Oertli, D., Kettelhack, C., Terracciano, L., & Tornillo, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24989 · Cited by 333

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer

Ladoire, S., Martin, F., & Ghiringhelli, F. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1046-y · Cited by 331

Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer

Ferris, R. L., Whiteside, T. L., & Ferrone, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2750 · Cited by 221

The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity

Khoury, S. J., & Sayegh, M. H. (2004) · Immunity · doi:10.1016/s1074-7613(04)00116-5 · Cited by 209

Tissue microarrays in drug discovery

Sauter, G., Simon, R., & Hillan, K. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1254 · Cited by 194

The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer

Roxburgh, C. S. D., & McMillan, D. C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.001 · Cited by 175

In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

Shin, T., Yoshimura, K., Shin, T., Crafton, E. B., Tsuchiya, H., Housseau, F., Koseki, H., Schulick, R. D., Chen, L., & Pardoll, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050072 · Cited by 159

Immunotherapy earns its spot in the ranks of cancer therapy

Pardoll, D. M., & Drake, C. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112275 · Cited by 136

Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma

Sconocchia, G., Zlobec, I., Lugli, A., Calabrese, D., Iezzi, G., Karamitopoulou, E., Patsouris, E., Peros, G., Horcic, M., Tornillo, L., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25609 · Cited by 116

Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: A potential role for dysregulation of the transforming growth factor-β pathway

Baker, K., Zlobec, I., Tornillo, L., Terracciano, L., Jass, J. R., & Lugli, A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.012 · Cited by 64

Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status

Lugli, A. K., Zlobec, I., Baker, K., Minoo, P., Tornillo, L., Terracciano, L., & Jass, J. R. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.039552 · Cited by 59

TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer

Zlobec, I., Karamitopoulou, E., Terracciano, L., Piscuoglio, S., Iezzi, G., Muraro, M. G., Spagnoli, G. C., Baker, K., Tzankov, A., & Lugli, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014282 · Cited by 58

Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma

Loos, M., Langer, R., Schuster, T., Gertler, R., Walch, A. K., Rauser, S., Frieß, H., & Feith, M. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2010.12.041 · Cited by 48

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324

Comprehensive review of targeted therapy for colorectal cancer

Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687

PD-L1 expression in human cancers and its association with clinical outcomes

Yu, J., Wang, X., Teng, F., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105862 · Cited by 787

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

Gatalica, Z., Snyder, C., Maney, T., Ghazalpour, A., Holterman, D. A., Xiao, N., Overberg, P., Rose, I., Basu, G. D., Vranic, S., et al. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0654 · Cited by 522

Prognostic and predictive value of PDL1 expression in breast cancer

Sabatier, R., Finetti, P., Mamessier, E., Adelaide, J., Chaffanet, M., Ali, H. R., Viens, P., Caldas, C., Birnbaum, D., & Bertucci, F. (2015) · Oncotarget · doi:10.18632/oncotarget.3216 · Cited by 508